## AMENDMENTS TO THE CLAIMS

Please cancel claims 63 and 66-93 without prejudice, as shown below.

Please amend claim 94 as shown in the following list of claims.

In compliance with 37 C.F.R. § 1.121, a complete listing of claims is presented below. This listing of claims will replace all prior versions and listings of claims in this application.

1-63. (Canceled)

64. (Withdrawn) The pharmaceutical composition of Claim 64 which is a lyophilized powder.

65. (Withdrawn) The pharmaceutical composition of Claim 64 which is a solution.

66-93. (Canceled)

94. (Currently amended) The pharmaceutical composition ~~of Claim 86~~ comprising an ApoA-I agonist and a pharmaceutically acceptable carrier, excipient or diluent;

wherein the ApoA-I agonist is in the form of an ApoA-I agonist-lipid complex, said complex comprising an ApoA-I agonist and a lipid,

wherein the ApoA-I agonist comprises:

~~(i)~~ a 22 to 29-residue peptide or peptide analogue which forms an amphipathic α-helix in the presence of lipids and which comprises formula (I):

$Z_1$-$X_1$-$X_2$-$X_3$-$X_4$-$X_5$-$X_6$-$X_7$-$X_8$-$X_9$-$X_{10}$-$X_{11}$-$X_{12}$-$X_{13}$-$X_{14}$-$X_{15}$-$X_{16}$-$X_{17}$-$X_{18}$-$X_{19}$-$X_{20}$-$X_{21}$-$X_{22}$-$X_{23}$-$Z_2$

or a pharmaceutically acceptable salt thereof, wherein:

$X_1$ is Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N), Asp (D) or D-Pro (p);

$X_2$ is an aliphatic residue;

$X_3$ is Leu (L) or Phe (F);

$X_4$ is an acidic residue;

$X_5$ is Leu (L) or Phe (F);

$X_6$ is Leu (L) or Phe (F);

$X_7$ is a hydrophilic residue;

$X_8$ is an acidic or a basic residue;

$X_9$ is Leu (L) or Gly (G);

$X_{10}$ is Leu (L), Trp (W) or Gly (G);

$X_{11}$ is a hydrophilic residue;

$X_{12}$ is a hydrophilic residue;

$X_{13}$ is Gly (G) or an aliphatic residue;

$X_{14}$ is Leu (L), Trp (W), Gly (G) or Nal;

$X_{15}$ is a hydrophilic residue;

$X_{16}$ is a hydrophobic residue;

$X_{17}$ is a hydrophobic residue;

$X_{18}$ is Gln (Q), Asn (N) or a basic residue;

$X_{19}$ is Gln (Q), Asn (N) or a basic residue;

$X_{20}$ is a basic residue;

$X_{21}$ is an aliphatic residue;

$X_{22}$ is a basic residue;

$X_{23}$ is absent or a basic residue;

$Z_1$ is $H_2N$- or RC(O)NR'-;

$Z_2$ is -C(O)NRR, -C(O)OR or -C(O)OH or a salt thereof;

each R is independently -H, ($C_1$-$C_6$) alkyl, ($C_1$-$C_6$) alkenyl, ($C_1$-$C_6$) alkynyl, ($C_5$-$C_{20}$) aryl, ($C_6$-$C_{26}$) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one or more bonds between residues 1-7 are independently a substituted amide, an isostere of an amide or an amide mimetic;

each R' is independently -H, ($C_1$-$C_6$) alkyl, ($C_1$-$C_6$) alkenyl, ($C_1$-$C_6$) alkynyl, ($C_5$-$C_{20}$) aryl, ($C_6$-$C_{26}$) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl; and

each "—" between residues $X_1$ through $X_{23}$ independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic;

~~(ii) a 15 to 26- residue peptide or peptide analogue according to formula (I) which forms an amphipathic α-helix in the presence of lipids wherein one or two helical turns are deleted from formula (I), wherein a helical turn consists of 3 to 4 consecutive residues selected from residues $X_1$ to $X_{23}$ of formula (I);~~

~~(iii) a 22 to 29- residue altered peptide or peptide analogue according to formula (I) in which at least one of residues $X_1$, $X_2$, $X_3$, $X_4$, $X_5$, $X_6$, $X_7$, $X_8$, $X_9$, $X_{10}$, $X_{11}$, $X_{12}$, $X_{13}$, $X_{14}$, $X_{15}$, $X_{16}$, $X_{17}$, $X_{18}$, $X_{19}$, $X_{20}$, $X_{21}$, $X_{22}$ or $X_{23}$ is conservatively substituted with another residue;~~ or

a N-terminally blocked form, a C-terminally blocked form, or an N- and C-terminally blocked form of formula (I).

95. (Previously presented) The pharmaceutical composition of Claim 94 wherein $X_7$ of the ApoA-I agonist is a basic residue.

96. (Previously presented) The pharmaceutical composition of Claim 94 wherein $X_3$, $X_6$, $X_9$ and $X_{10}$ of the ApoA-I agonist are hydrophobic residues.

97. (Previously presented) The pharmaceutical composition of Claim 94 wherein the ApoA-I agonist is a 22-23 residue peptide or peptide analogue according to formula (I).

98. (Previously presented) The pharmaceutical composition of Claim 97 comprising an ApoA-I agonist according to formula (I) wherein:

the "—" between residues $X_1$ through $X_{23}$ designates -C(O)NH-;

$Z_1$ is $H_2N$-; and

$Z_2$ is -C(O)OH or a salt thereof.

99. (Previously presented) The pharmaceutical composition of Claim 98 comprising an ApoA-I agonist according to formula (I) wherein:

$X_1$ is Pro (P), Ala (A), Gly (G), Asn (N), Gln (Q), Asp (D) or D-Pro (p);

$X_2$ is Ala (A), Val (V) or Leu (L);

$X_3$ is Leu (L) or Phe (F);

$X_4$ is Asp (D) or Glu (E);

$X_5$ is Leu (L) or Phe (F);

$X_6$ is Leu (L) or Phe (F);

$X_7$ is Lys (K), Arg (R) or Orn;

$X_8$ is Asp (D) or Glu (E);

$X_9$ is Leu (L) or Gly (G);

$X_{10}$ is Leu (L), Trp (W) or Gly (G);

$X_{11}$ is Asn (N) or Gln (Q);

$X_{12}$ is Glu (E) or Asp (D);

$X_{13}$ is Gly (G), Leu (L) or Aib;

$X_{14}$ is Leu (L), Nal, Trp (W) or Gly (G);

$X_{15}$ is Asp (D) or Glu (E);

$X_{16}$ is Ala (A), Nal, Trp (W), Leu (L), Phe (F) or Gly (G);

$X_{17}$ is Gly (G), Leu (L) or Nal;

$X_{18}$ is Gln (Q), Asn (N), Lys (K) or Orn;

$X_{19}$ is Gln (Q), Asn (N), Lys (K) or Orn;

$X_{20}$ is Lys (K) or Orn;

$X_{21}$ is Leu (L);

$X_{22}$ is Lys (K) or Orn; and$X_{23}$ is absent or Lys (K).

100. (Previously presented) The pharmaceutical composition of Claim 99 wherein $X_{23}$ of the ApoA-I agonist is absent.

101. (Previously presented) The pharmaceutical composition of Claim 94 comprising an ApoA-I agonist according to formula (I ) wherein one of $X_{18}$ or $X_{19}$ is Gln (Q) or Asn (N) and the other of $X_{18}$ or $X_{19}$ is Lys (K) or Orn.

102. (Withdrawn) The pharmaceutical composition of Claim 94 comprising an ApoA-I agonist according to formula (I) wherein each of $X_9$, $X_{10}$, $X_{13}$, $X_{14}$, $X_{16}$ and $X_{17}$ is Gly (G ) and the others are other than Gly (G).

103. (Previously presented) The pharmaceutical composition of Claim 94 comprising an ApoA-I agonist selected from the group consisting of:

| | | |
|---|---|---|
| peptide **1** | PVLDLFRELLNELLEZLKQKLK | (SEQ ID NO:1) |
| peptide **2** | GVLDLFRELLNELLEALKQKLKK | (SEQ ID NO:2) |
| peptide **3** | PVLDLFRELLNELLEWLKQKLK | (SEQ ID NO:3) |
| peptide **4** | PVLDLFRELLNELLEALKQKLK | (SEQ ID NO:4) |
| peptide **5** | pVLDLFRELLNELLEALKQKLKK | (SEQ ID NO:5) |
| peptide **6** | PVLDLFRELLNEXLEALKQKLK | (SEQ ID NO:6) |
| peptide **7** | PVLDLFKELLNELLEALKQKLK | (SEQ ID NO:7) |
| peptide **8** | PVLDLFRELLNEGLEALKQKLK | (SEQ ID NO:8) |
| peptide **9** | PVLDLFRELGNELLEALKQKLK | (SEQ ID NO:9) |
| peptide **10** | PVLDLFRELLNELLEAZKQKLK | (SEQ ID NO:10) |
| peptide **11** | PVLDLFKELLQELLEALKQKLK | (SEQ ID NO:11) |
| peptide **12** | PVLDLFRELLNELLEAGKQKLK | (SEQ ID NO:12) |
| peptide **13** | GVLDLFRELLNEGLEALKQKLK | (SEQ ID NO:13) |
| peptide **14** | PVLDLFRELLNELLEALOQOLO | (SEQ ID NO:14) |
| peptide **15** | PVLDLFRELWNELLEALKQKLK | (SEQ ID NO:15) |
| peptide **16** | PVLDLLRELLNELLEALKQKLK | (SEQ ID NO:16) |
| peptide **17** | PVLELFKELLQELLEALKQKLK | (SEQ ID NO:17) |

| | | |
|---|---|---|
| peptide **18** | GVLDLFRELLNELLEALKQKLK | (SEQ ID NO:18) |
| peptide **19** | pVLDLFRELLNEGLEALKQKLK | (SEQ ID NO:19) |
| peptide **20** | PVLDLFREGLNELLEALKQKLK | (SEQ ID NO:20) |
| peptide **21** | pVLDLFRELLNELLEALKQKLK | (SEQ ID NO:21) |
| peptide **22** | PVLDLFRELLNELLEGLKQKLK | (SEQ ID NO:22) |
| peptide **23** | PLLELFKELLQELLEALKQKLK | (SEQ ID NO:23) |
| peptide **24** | PVLDLFRELLNELLEALQKKLK | (SEQ ID NO:24) |
| peptide **25** | PVLDFFRELLNEXLEALKQKLK | (SEQ ID NO:25) |
| peptide **26** | PVLDLFRELLNELLELLKQKLK | (SEQ ID NO:26) |
| peptide **27** | PVLDLFRELLNELZEALKQKLK | (SEQ ID NO:27) |
| peptide **28** | PVLDLFRELLNELWEALKQKLK | (SEQ ID NO:28) |
| peptide **29** | AVLDLFRELLNELLEALKQKLK | (SEQ ID NO:29) |
| peptide **123** | QVLDLFRELLNELLEALKQKLK | (SEQ ID NO:123) |
| peptide **124** | PVLDLFOELLNELLEALOQOLO | (SEQ ID NO:124) |
| peptide **125** | NVLDLFRELLNELLEALKQKLK | (SEQ ID NO:125) |
| peptide **126** | PVLDLFRELLNELGEALKQKLK | (SEQ ID NO:126) |
| peptide **127** | PVLDLFRELLNELLELLKQKLK | (SEQ ID NO:127) |
| peptide **128** | PVLDLFRELLNELLEFLKQKLK | (SEQ ID NO:128) |
| peptide **129** | PVLELFNDLLRELLEALQKKLK | (SEQ ID NO:129) |
| peptide **130** | PVLELFNDLLRELLEALKQKLK | (SEQ ID NO:130) |
| peptide **131** | PVLELFKELLNELLDALRQKLK | (SEQ ID NO: 131) |
| peptide **132** | PVLDLFRELLENLLEALQKKLK | (SEQ ID NO:132) |
| peptide **133** | PVLELFERLLEDLLQALNKKLK | (SEQ ID NO:133) |
| peptide **134** | PVLELFERLLEDLLKALNQKLK | (SEQ ID NO:134) |
| peptide **135** | DVLDLFRELLNELLEALKQKLK | (SEQ ID NO:135) |
| peptide **136** | PALELFKDLLQELLEALKQKLK | (SEQ ID NO:136) |
| peptide **137** | PVLDLFRELLNEGLEAZKQKLK | (SEQ ID NO:137) |
| peptide **138** | PVLDLFRELLNEGLEWLKQKLK | (SEQ ID NO:138) |
| peptide **139** | PVLDLFRELWNEGLEALKQKLK | (SEQ ID NO:139) |
| peptide **140** | PVLDLFRELLNEGLEALOQOLO | (SEQ ID NO:140) |
| peptide **141** | PVLDFFRELLNEGLEALKQKLK | (SEQ ID NO:141) |
| peptide **142** | PVLELFRELLNEGLEALKQKLK | (SEQ ID NO:142) |

and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof, wherein X is Aib; Z is Nal; and O is Orn.

104. (Previously presented) The pharmaceutical composition of Claim 103 comprising an ApoA-I agonist that is SEQ ID NO: 4.

105. (Withdrawn) The pharmaceutical composition of Claim 94 comprising an ApoA-I agonist that is an altered form of formula (I).

106. (Withdrawn) The pharmaceutical composition of Claim 94 comprising an ApoA-I agonist wherein residues $X_2$, $X_3$, $X_5$, $X_6$, $X_9$, $X_{10}$, $X_{13}$, $X_{14}$, $X_{16}$, $X_{17}$ and $X_{21}$ are fixed according to formula I and at least one of residues $X_1$, $X_4$, $X_7$, $X_8$, $X_{11}$, $X_{12}$, $X_{15}$, $X_{18}$, $X_{19}$, $X_{20}$ and $X_{22}$ is conservatively substituted with another residue.

107. (Withdrawn) The pharmaceutical composition of Claim 105 comprising an ApoA-I agonist wherein:

$X_1$ is Pro (P), D-Pro (p), Gly (G) or Ala (A);

$X_2$ is Ala (A), Leu (L) or Val (V);

$X_3$ is Leu (L) or Phe (F);

$X_5$ is Leu (L) or Phe (F);

$X_6$ is Leu (L) or Phe (F);

$X_9$ is Leu (L) or Gly (G);

$X_{10}$ is Leu (L), Trp (W) or Gly (G);

$X_{13}$ is Leu (L), Gly (G) or Aib;

$X_{14}$ is Leu (L), Nal, Trp (W) or Gly (G);

$X_{16}$ is Ala (A), Nal, Trp (W), Gly (G), Leu (L) or Phe (F);

$X_{17}$ is Leu (L), Gly (G) or Nal;

$X_{21}$ is Leu (L); and

at least one of $X_4$, $X_7$, $X_8$, $X_{11}$, $X_{12}$, $X_{15}$, $X_{18}$, $X_{19}$, $X_{20}$, $X_{22}$ and $X_{23}$ is conservatively substituted with another residue.

108. (Withdrawn) The pharmaceutical composition of Claim 94 comprising an ApoA-I agonist wherein $X_4$, $X_7$, $X_8$, $X_{11}$, $X_{12}$, $X_{15}$, $X_{18}$, $X_{19}$ and $X_{22}$ are fixed according to formula I and

at least one of residues $X_2$, $X_3$, $X_5$, $X_6$, $X_9$, $X_{10}$, $X_{13}$, $X_{14}$, $X_{16}$, $X_{17}$, $X_{20}$ and $X_{21}$ is conservatively substituted with another residue.

109. (Withdrawn) The pharmaceutical composition of Claim 108 comprising an ApoA-I agonist wherein:

$X_4$ is Asp (D) or Glu (E);

$X_7$ is Lys (K), Arg (R) or Orn;

$X_8$ is Asp (D) or Glu (E);

$X_{11}$ is Asn (N) or Gln (Q);

$X_{12}$ is Glu (E) or Asp (D);

$X_{15}$ is Asp (D) or Glu (E);

$X_{18}$ is Gln (Q), Asn (N), Lys (K) or Orn;

$X_{19}$ is Gln (Q), Asn (N), Lys (K) or Orn;

$X_{20}$ is Lys (K) or Orn;

$X_{22}$ is Lys (K) or Orn;

$X_{23}$ is absent or Lys (K); and

at least one of $X_1$, $X_2$, $X_3$, $X_5$, $X_6$, $X_9$, $X_{10}$, $X_{13}$, $X_{14}$, $X_{16}$, $X_{17}$ and $X_{21}$ is conservatively substituted with another residue.

110. (Previously presented) The pharmaceutical composition of Claim 94 comprising an ApoA-I agonist wherein $X_3$ is Leu (L) or Phe (F), $X_6$ is Phe (F), $X_9$ is Leu (L) or Gly (G), and $X_{10}$ is Leu (L), Trp (W) or Gly (G).

111. (Withdrawn) The pharmaceutical composition of Claim 94 comprising an ApoA-I agonist wherein one helical turn is deleted.

112. (Withdrawn) The pharmaceutical composition of Claim 94 comprising an ApoA-I agonist wherein three, four, six, seven or eight residues $X_1$ , $X_2$ , $X_3$ , $X_4$ , $X_5$ , $X_6$ , $X_7$ , $X_8$ , $X_9$ , $X_{10}$ , $X_{11}$ , $X_{12}$ , $X_{13}$ , $X_{14}$ , $X_{15}$ , $X_{16}$ , $X_{17}$ , $X_{18}$ , $X_{19}$ , $X_{20}$ , $X_{21}$ and $X_{22}$ are deleted.

113. (Withdrawn) The pharmaceutical composition of Claim 112 comprising an ApoA-I agonist wherein 3 consecutive residues are deleted.

114. (Withdrawn) The pharmaceutical composition of Claim 112 comprising an ApoA-I agonist wherein 4 consecutive residues are deleted.

115. (Withdrawn) The pharmaceutical composition of Claim 112 comprising an ApoA-I agonist wherein two non-contiguous sets of 3 consecutive residues are deleted.

116. (Withdrawn) The pharmaceutical composition of Claim 112 comprising an ApoA-I agonist wherein two non-contiguous sets of 4 consecutive residues are deleted.

117. (Withdrawn) The pharmaceutical composition of Claim 112 comprising an ApoA-I agonist wherein one set of 3 consecutive residues and one set of 4 consecutive residues are deleted.

118. (Withdrawn) The pharmaceutical composition of Claim 112 comprising an ApoA-I agonist wherein 6, 7 or 8 consecutive residues are deleted.

119. (Withdrawn) A method of treating dyslipidemia in a subject in need of such treatment, said method comprising administering to the subject an effective amount of the pharmaceutical composition of Claim 63 or 86.

120. (Withdrawn) The method of Claim 119 wherein the dyslipidemia is atherosclerosis.

121. (Withdrawn) The method of Claim119 wherein the dyslipidemia is cardiovascular disease.

122. (Withdrawn) The method of Claim 119 wherein said subject is human.

123. (Withdrawn) The method of Claim 119 wherein the pharmaceutical composition is administered intravenously.

124. (Withdrawn) The method of Claim 119 wherein the pharmaceutical composition is administered once weekly.

125. (Withdrawn) A method of treating septic shock in a subject in need of such treatment, said method comprising administering to the subject an effective amount of the pharmaceutical composition of Claim63 or 86.

126. (Withdrawn) The method of Claim 125 wherein said subject is human.

127. (Withdrawn) The method of Claim 125 wherein the pharmaceutical composition is administered intravenously.